PMID- 34329715
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 280
DP  - 2021 Nov 15
TI  - The role of traditional Chinese medicine in the treatment of cognitive 
      dysfunction in type 2 diabetes.
PG  - 114464
LID - S0378-8741(21)00693-0 [pii]
LID - 10.1016/j.jep.2021.114464 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Diabetic cognitive dysfunction (DCD) is mainly 
      one of the complications of type 2 diabetes mellitus (T2DM) with complex and 
      obscure pathogenesis. Extensive evidence has demonstrated the effectiveness and 
      safety of traditional Chinese medicine (TCM) for DCD management. AIM OF THE 
      STUDY: This review attempted to systematically summarize the possible 
      pathogenesis of DCD and the current Chinese medicine on the treatment of DCD. 
      MATERIALS AND METHODS: We acquired information of TCM on DCD treatment from 
      PubMed, Web of Science, Science Direct and CNKI databases. We then dissected the 
      potential mechanisms of currently reported TCMs and their active ingredients for 
      the treatment of DCD by discussing the deficiencies and giving further 
      recommendations. RESULTS: Most TCMs and their active ingredients could improve 
      DCD through alleviating insulin resistance, microvascular dysfunction, abnormal 
      gut microbiota composition, inflammation, and the damages of the blood-brain 
      barrier, cerebrovascular and neurons under hyperglycemia conditions. CONCLUSIONS: 
      TCM is effective in the treatment of DCD with few adverse reactions. A large 
      number of in vivo and in vitro, and clinical trials are still needed to further 
      reveal the potential quality markers of TCM on DCD treatment.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Meng, Jinni
AU  - Meng J
AD  - Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 
      Ningxia, China.
FAU - Zhu, Yafei
AU  - Zhu Y
AD  - College of Basic Medicine, Ningxia Medical University, Ningxia, China.
FAU - Ma, Huixia
AU  - Ma H
AD  - Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 
      Ningxia, China.
FAU - Wang, Xiaobo
AU  - Wang X
AD  - State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative 
      Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China. Electronic address: 1461875871@qq.com.
FAU - Zhao, Qipeng
AU  - Zhao Q
AD  - Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 
      Ningxia, China; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of 
      Education, Ningxia Medical University, Ningxia, China. Electronic address: 
      zhqp623@126.com.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20210727
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Animals
MH  - Cognitive Dysfunction/*drug therapy/etiology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology
MH  - Drugs, Chinese Herbal/adverse effects/*pharmacology
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Medicine, Chinese Traditional/methods
OTO - NOTNLM
OT  - Central nervous system
OT  - Hyperglycemia
OT  - Insulin resistance
OT  - Mechanisms
OT  - TCM
EDAT- 2021/07/31 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/07/30 20:11
PHST- 2021/04/03 00:00 [received]
PHST- 2021/07/04 00:00 [revised]
PHST- 2021/07/24 00:00 [accepted]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/07/30 20:11 [entrez]
AID - S0378-8741(21)00693-0 [pii]
AID - 10.1016/j.jep.2021.114464 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2021 Nov 15;280:114464. doi: 10.1016/j.jep.2021.114464. Epub 
      2021 Jul 27.